search
Back to results

OT and Social Cognition in Children With ADHD: Impact of MPH

Primary Purpose

Attention Deficit Hyperactivity Disorder

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ritalin
Sponsored by
Shalvata Mental Health Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Attention Deficit Hyperactivity Disorder

Eligibility Criteria

6 Years - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Ages 6-12 years
  • Diagnosis of ADHD

Exclusion Criteria:

  • Past or current affective disorder, psychosis, substance abuse, conduct disorder
  • Any medical or neurological condition or medication-taking that might affect the child's participation in the study
  • First-degree relative with a major psychiatric diagnosis

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    ADHD group

    Healthy control

    Arm Description

    This group was examined twice - once after taking Ritalin and once after taking placebo

    Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD

    Outcomes

    Primary Outcome Measures

    changes in scores of ToM test
    ToM test - consists of vignettes, stories, and drawings about which the child has to answer a number of questions.
    changes in scores of Faux-Pas Recognition test
    number of faux-pas recognized in specific vignettes by participants
    changes in Oxytocin salivary level
    Oxytocin salivary levels as measured three/two times during the examination (ADHD group and healthy control accordingly).

    Secondary Outcome Measures

    Full Information

    First Posted
    December 19, 2018
    Last Updated
    December 26, 2018
    Sponsor
    Shalvata Mental Health Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03788902
    Brief Title
    OT and Social Cognition in Children With ADHD: Impact of MPH
    Official Title
    Oxytocin and Social Cognition in Children With Attention Deficit Hyperactivity Disorder: Impact of Methylphenidate
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    February 1, 2014 (Actual)
    Primary Completion Date
    December 1, 2016 (Actual)
    Study Completion Date
    January 1, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Shalvata Mental Health Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Background: The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide found to regulate social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD) compared to healthy controls (HCs). Methods: In a double-blind manner the investigators compared the performance of 50 children with ADHD and 40 HCs in "theory of mind" (ToM) tasks and examined the effect of a single dose of MPH/placebo on ToM and salivary OT levels in children with ADHD at baseline and following an interpersonal interaction.
    Detailed Description
    Attention deficit hyperactivity disorder (ADHD), a neurodevelopmental disorder affecting approximately 7% of children and adolescents, is associated with considerable impairments in social functioning. Children with ADHD, in comparison to healthy children, suffer from more social rejection and problems in reciprocal relationships. Deficits in interpersonal functioning in children with ADHD have been attributed in previous studies to, among other things, impairments in theory of mind (ToM) - the ability to attribute mental states, beliefs, and intentions to self and to others. For example, some studies have shown deficits in the ability to recognize facial expressions among children with ADHD. Other studies have found impairments in first- and second-order ToM tests. There is also evidence showing that empathic functions in children with ADHD are impaired. However, small sample sizes, as well as high percentages of comorbid disruptive disorders, served as limitations in these studies. One's ToM ability depends on, among other things, the integrity of dopaminergic and serotonergic systems, as well as on their interaction with other neurotransmitters and neurohormones (e.g., acetylcholine, oxytocin). Oxytocin (OT) is a neuropeptide found to accelerate the formation of social relationships, the expression of behaviors of closeness, and the recognition of affect in the facial expressions of others. Oxytocin has been hypothesized to raise the salience of social cues by modulating attention-orienting responses to external contextual social cues. Its secretion increases in response to interpersonal interactions. Studies found connections between blood and saliva OT levels, OT receptor gene polymorphism, and the strength of social relationships and behaviors in healthy individuals, as well as in patients suffering from mental disorders. Oxytocin reciprocally interacts with dopaminergic neurons in the mesolimbic tract. Anatomical and immonucytochemical studies have found that neuronal fibers and receptor binding-sites of OT and dopamine are located in the same areas in the central nervous system (CNS), sometimes in very close proximity to one another. Oxytocin-secreting cells in the hypothalamus carry dopamine receptors. Indeed, patients with mental disorders related to dysregulation of dopamine (e.g., autistic spectrum disorders, schizophrenia, depression) show changes in their CNS and peripheral OT levels. Given the fact that injury of dopaminergic transporters and receptors is a central component in the etiology of ADHD, it is also possible that OT plays a role as a mediator of social deficits, and mainly in ToM impairment in children with ADHD. To date, only a few studies have shown decreased OT levels in children with ADHD when compared to healthy controls. These studies found a negative correlation between serum OT levels and ADHD rating scale total scores, and aggression scores, and a positive correlation between the serum OT level and empathy scores in patients with ADHD. However, in both studies, only baseline OT levels were assessed; therefore, changes in OT levels following an interpersonal interaction were not measured. This is an important point, as social abilities are dynamic and interaction-related; the reactivity of the OT system to interpersonal interaction is thus probably highly relevant to the understanding of social difficulties in ADHD patients. Stimulants reduce negative social interactions and improve social and behavioral functioning in children with ADHD, and also improve empathy scores. In a previous study, the investigators showed that a single dose of methylphenidate (MPH) improved the performance of children with ADHD on ToM tests. To date, no study examined a possible effect of stimulants on OT levels in children with ADHD. This is a pivotal issue in the understanding of the neurobiological underpinnings of improvement in social cognition measures among children with ADHD who are treated with stimulants, given that OT might have a role in mediating this improvement. In the current study the investigators hypothesized that dysfunction in the OT system may account for the social difficulties of children suffering from ADHD and that the dynamics in the OT system may explain the pro-social effect of stimulants on these children. Thus, the objectives of the current study were 1) to compare ToM measures and salivary OT levels between children with ADHD and healthy controls (HCs), and 2) to examine the effect of a single dose of MPH on ToM and salivary OT levels in children with ADHD following an interpersonal interaction. Methods Subjects Fifty children aged 6-12 diagnosed with ADHD and 40 HCs were recruited. Patients were recruited from the ADHD clinic and the outpatient clinic of the Shalvata Mental Health Center, School of Medicine, Tel-Aviv University. The HCs subjects were recruited from the community via the internet and social media. ADHD was diagnosed by child and adolescent psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders, fourth or fifth edition (DSM-IV-TR and DSM-5). The investigators excluded children with a past or current affective disorder, psychosis, substance abuse, conduct disorder or any medical or neurological condition or medication-taking that might affect the child's participation in the study. The investigators also excluded children who had a first-degree relative with a major psychiatric diagnosis. Inclusion criteria for the control group were the same as those of the ADHD group but with no diagnosis of ADHD or a first-degree relative with ADHD. Participants were reimbursed for their expanses in participation and received a small present as appreciation. The IRB approved the study. Both parents of all participants signed a consent form and the children gave their consent verbally. Procedure Apart from the initial clinical assessment at the clinic, all assessments were performed in the children's homes. Children with ADHD participated in two sessions: one session an hour after taking a short-acting MPH (in an adjusted dosage of 0.3-0.5mg/kg) and one session an hour after taking a placebo (PLC). Children routinely prescribed with MPH treatment were asked not to take the medicine 48 hours before the examination, since the clinical effect of the long-acting MPH is no longer than 12 hours. The study was randomized-controlled, such that children were assigned to the sessions randomly in a double-blind manner. Each session lasted about 60-90 minutes. In order to lessen a possible learning effect of the computerized tasks (to be elaborated upon forthwith), the sessions were performed at least two weeks apart. Control subjects participated in only one session and did not take any medication. Parents completed questionnaires regarding demographics and general information about the child's academic and social functioning. In addition, parents completed the Swanson, Nolan and Pelham Questionnaire-IV (SNAP-IV). This instrument contains subscales for inattention, hyperactive/impulsive behavior, and oppositional behavior. Parents also filled out the Strengths and Difficulties Questionnaire (SDQ), a screening inventory composed of five distinct dimensions: conduct problems, emotional symptoms, hyperactivity, peer problems, and pro-social behavior. Intelligence was measured using the similarities subtest from the Wechsler Intelligence Scale for Children version IV (WISC-IV). Self-reported anxiety was measured using the State-Trait Anxiety Inventory (STAI), a 40-item questionnaire scored by a Likert scale. State anxiety represents a transient emotional status that results from situational stress; trait anxiety represents a predisposition to react with anxiety in stressful situations. The investigators measured ToM performance using the ToM test, which test consists of vignettes, stories, and drawings about which the child has to answer a number of questions. Results are given on three subscales: ToM1 - precursors of ToM (i.e., recognition of emotions); ToM2 - first manifestations of a real ToM (first-order belief, understanding of false belief); and ToM3 - more advanced aspects of ToM (second-order belief, understanding of humor). The second ToM task was the Faux Pas Recognition task (FPR), designed by Baron-Cohen et al.. This task is designated to evaluate the ability of participants to recognize social "faux pas" - social situations in which a speaker says something without understanding that there might be a difference between his/her state of knowledge and that of the listener ("cognitive" ToM), and should recognize the potential emotional impact of a statement on the listener ("affective" ToM). At each session, participants were given 10 short stories, five of which contained faux pas situations to be identified. After hearing every story, participants were asked ToM questions. The score consisted of the total number of all correct identifications of a faux pas situation. The Hebrew version of the FPR was employed after validation by a group of normative subjects. Executive functions and attention were tested via the cognition module in the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB). The investigators used the Dimensional Change Card Sort Test (DCCS) and the Flanker Inhibitory Control and Attention Test, which measure cognitive flexibility and inhibitory control, respectively. Salivary OT levels were measured at three time points: at the beginning of each session ("T1"), 40 minutes after the administration of MPH/PLC ("T2"; only for the ADHD group), and 15 minutes after a "positive social interaction" in which the child and the parent were asked to plan a "fun day" that would include both of them, and to talk about it for five minutes ("T3"). Participants were asked to avoid drinking and eating an hour before the test and to avoid caffeine three hours before the test. Saliva samples were collected by passive drool. In order to precipitate the mucus, samples underwent three freeze-thaw cycles: freeze at -70°C and thaw at 4°C. After the forth cycle the tubes were centrifuged twice at 1500 x g (4000 rpm) for 30 minutes. Supernatants were collected and stored at -20°C until assayed. Determination of OT from saliva samples was performed using a commercial OT ELISA kit (ENZO, NY, USA). Measurements were performed in duplicate according to the manufacturer's instructions. The concentrations of samples were calculated using MatLab-7 according to relevant standard curves. The intra-assay and inter-assay coefficients of samples were 14.7 and 22.7 percent, respectively. The intra-assay and inter-assay coefficients of controls were 4.9 and 13.2 percent, respectively.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Attention Deficit Hyperactivity Disorder

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    90 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    ADHD group
    Arm Type
    Experimental
    Arm Description
    This group was examined twice - once after taking Ritalin and once after taking placebo
    Arm Title
    Healthy control
    Arm Type
    No Intervention
    Arm Description
    Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
    Intervention Type
    Drug
    Intervention Name(s)
    Ritalin
    Intervention Description
    Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
    Primary Outcome Measure Information:
    Title
    changes in scores of ToM test
    Description
    ToM test - consists of vignettes, stories, and drawings about which the child has to answer a number of questions.
    Time Frame
    20 minutes
    Title
    changes in scores of Faux-Pas Recognition test
    Description
    number of faux-pas recognized in specific vignettes by participants
    Time Frame
    15 minutes
    Title
    changes in Oxytocin salivary level
    Description
    Oxytocin salivary levels as measured three/two times during the examination (ADHD group and healthy control accordingly).
    Time Frame
    2 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Years
    Maximum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Ages 6-12 years Diagnosis of ADHD Exclusion Criteria: Past or current affective disorder, psychosis, substance abuse, conduct disorder Any medical or neurological condition or medication-taking that might affect the child's participation in the study First-degree relative with a major psychiatric diagnosis
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Hagai Maoz, MD
    Organizational Affiliation
    Shalvata Mental Health Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    OT and Social Cognition in Children With ADHD: Impact of MPH

    We'll reach out to this number within 24 hrs